Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tracon could get rights to two Janssen oncology candidates

Executive Summary

Janssen Pharmaceutica NV licensed Tracon Pharmaceuticals Inc. rights to develop, manufacture, and commercialize two preclinical cancer compounds--JNJ63576253 (renamed TRC253), an inhibitor of wild type androgen receptor (AR) and multiple AR mutations aimed at prostate cancer; and JNJ64290694 (TRC694), an inhibitor of NF-kB inducing kinase (NIK) for treating hematologic malignancies including myeloma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Reverse Licensing

Related Companies